Literature DB >> 19811416

Serum levels of soluble fas in patients with multinodular goiter.

Maria Andrikoula1, Nikolaos Kolaitis, George Vartholomatos, Agathocles Tsatsoulis.   

Abstract

OBJECTIVE: Fas is a cell-surface receptor responsible for induction of apoptosis in human thyrocytes upon interaction with Fas Ligand. Fas protein expression on thyroid cells and Fas-mediated apoptosis is decreased in multinodular goiter (MNG) resulting in thyroid cell proliferation. The soluble form of Fas (sFas) produced by alternative mRNA splicing may inhibit Fas-Fas Ligand binding and apoptosis. The aim of this study was to examine whether sFas is differentially expressed in multinodular goiter (MNG), which is associated with decreased Fas-mediated apoptosis.
METHOD: We determined serum sFas levels using enzyme-linked immunosorbent assay (ELISA) in 42 patients with MNG and 23 normal controls.
RESULTS: Serum sFas levels were increased in patients with MNG (7.47 +/- 2.55 ng/ml) compared to normal controls (2.26 +/- 0.9 ng/ml). Levels of sFas were not significantly correlated with age, sex or clinical parameters, such as serum levels of FT4 or TSH. DISCUSSION: Increased sFas in MNG may indicate increased expression of alternatively spliced Fas mRNA variant and decreased expression of cell-surface Fas protein, and may enhance thyroid cell proliferation by protecting thyroid cells from Fas-mediated apoptosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19811416     DOI: 10.1080/08820130902912324

Source DB:  PubMed          Journal:  Immunol Invest        ISSN: 0882-0139            Impact factor:   3.657


  1 in total

1.  Influence of levothyroxine treatment on serum levels of soluble Fas (CD95) and Fas Ligand (CD95L) in chronic autoimmune hypothyroidism.

Authors:  Iraj Nabipour; Mohammadreza Kalantarhormozi; Majid Assadi; Seyed Mojtaba Jafari; Mohammad Gharibi; Esmaeil Ahmadi; Zahra Sanjdideh
Journal:  Endocrine       Date:  2010-11-02       Impact factor: 3.633

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.